Understanding the opportunity in Japan's biosimilar market.

Autor:	Kim, Minyoung, Monnard, Alex, da Silva, Jorge Santos da
Předmět:	MEDICAL personnel MARKETS CROHN'S disease MARKETING
Zdroj:	McKinsey Insights; 9/20/2019, pN.PAG-N.PAG, 1p, 3 Color Photographs
Abstrakt:	Despite a sluggish start, Japan's biosimilar market looks set for accelerated growth. Or they should target sizable subgroups of patients whose treatment with biosimilars could hit the co-pay cap and thus lower patient costs in line with those of the originators. For example, prescriptions for adalimumab for elderly patients could reach the cap, as the elderly are likely to be taking several different drugs, the combined costs of which would be considered under the co-pay system. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.